Exploiting the graft-versus-leukemia (GVL) effect in mismatched transplants requires its separation from graftversus-host disease (GVHD). We generated leukemiaspecific cytotoxic T lymphocytes (CTL) in three haplotype-mismatched, two class I-mismatched and two single HLA-A locus-matched stimulator-responder pairs. Six patients with chronic myelogenous leukemia and one patient with acute myeloid leukemia transformed from MDS were studied. CTL generated after 10 days stimulation with unselected leukemic peripheral blood mononuclear cells inhibited leukemic CFU-GM colony growth (485% at 10:1 effector:target ratio) with no third-party colony inhibition. In five pairs, responders were cultured separately with leukemia cells, PHA-B or LCL from the stimulator. After 2-4 restimulations, the T cell repertoire was examined by flow analysis using Vb-specific antibodies. Test cultures (but not controls) showed preferential expansion of 1-4 Vb families either common to two or more stimulators or unique to a particular stimulator. Notably, we elicited leukemia-specific TCR Vb expansions on four out of five occasions. In two pairs, responder cells selected for the appropriate leukemia-specific Vb family were shown to have leukemia-specific cytotoxicity. These leukemia-restricted T-cells were CD8+ or CD4+ and CD25+ or CD57+. The results support the development of strategies to selectively deplete GVHD and conserve GVL reactivity in mismatched transplants. Bone Marrow Transplantation (2003) 32, 371-378. doi:10.1038/sj.bmt.1704142
The curative effect of allogeneic bone marrow transplantation (allo-BMT) from an HLA-identical donor is well established for a variety of hematological malignancies. 1 Nevertheless, despite the increasing availability of unrelated donors, a suitable HLA-identical donor cannot be identified in a timely fashion for at least 50% of patients. 2, 3 Animal transplantation models indicate that powerful antitumor cytotoxic T lymphocyte (CTL) can be elicited in an MHC-mismatched setting. 4, 5 These observations support limited clinical experience in HLA-mismatched transplants indicating a strong graft-versus-leukemia (GVL) effect in high-risk patients with advanced leukemia and in leukemia relapsing after BMT treated with donor lymphocyte infusions. [6] [7] [8] [9] However, it is also clear that HLA disparity increases the risk of severe graft-versus-host disease (GVHD). [10] [11] [12] As a result of the risk from GVHD, current HLA-mismatched transplant protocols use T cell depletion and potent immunosuppression to prevent GVHD, which in turn compromises the GVL effect. Separation of GVL alloresponses from the GVHD T cell alloresponse would permit the full exploitation of the therapeutic effect of the haplotype-mismatched transplant. Previous studies in HLA-matched transplants have defined an immunological basis for separating T cell clones with GVHD or GVL alloresponsiveness; while many alloantigens are shared between hematopoietic and nonhematopoietic tissue, there are also opportunities for specific clonal T cell responses to antigens presented only by leukemia cells or hematopoietic cells, which make possible GVL (or graft-versus-marrow)-specific alloresponses. These tissue-restricted antigens have been identified either as minor histocompatibility antigens or nonallelic leukemiarestricted antigens. [13] [14] [15] [16] The question remains whether such tissue-restricted responses can also be elicited in HLA-mismatched donorrecipient pairs. To study this possibility, we examined alloresponses between mismatched unrelated stimulatorresponder pairs. Here we report preliminary observations indicating that tissue-restricted (including leukemiarestricted) alloresponses can regularly be identified in an HLA class I or II-mismatched context.
Materials and methods

Patients and responders
Patients. Peripheral blood mononuclear cells (PBMC) were obtained from a cryopreserved leukapheresis collection obtained prior to stem cell transplant from six patients, with chronic myelogenous leukemia (CML), five in chronic phase (CP), one in myeloid blastic crisis (MBC) and one patient with acute myeloid leukemia (AML) evolved from myelodysplastic syndrome. Acute leukemia samples contained over 80% circulating leukemic blasts. Myeloid leukemia cells were obtained from patient's PBMC by negative depletion with anti-CD2/CD19 magnetic beads according to the manufacturer's instructions (Dynabeads, Dynal, Inc., Oslo, Norway). Selected leukemic fractions contained o3% CD2 positive cells and o1% CD19 positive cells. Phytohemagglutinin-transformed cells (PHA-B) and EBV-transformed cell (LCL) were prepared using standard methods. 17 Responders. Normal responder cells, selected according to their HLA type, were obtained from cryopreserved lymphocyte apheresis collections from five normal stem cell donors unrelated to the patients studied. All patients and donors gave written informed consent for research apheresis collections in NIH protocols 97-H-0099 and 99-H-0046.
CTL generation. A total of 10 million normal donor PBMC were cocultured with equal numbers of irradiated patient cells in 75 ml flasks for 10 days in 20 ml of RPMI-1640 complete medium (10 mmol/l HEPES buffer, 2 mmol/l l-glutamine, 0.065 mg/ml gentamicin, GIBCO-BRL, Gaithersburg, MD, USA) supplemented with 10% heatinactivated pooled human AB serum (NABS; Gemini BioProducts, Woodland, CA, USA). On days 4 and 7, 100 IU/ ml recombinant human interleukin-2 (rh IL-2; Tecint, Roche Pharmaceutical, Indianapolis, IN, USA) was added. Stimulator cells used were either unselected 25-Gy-irradiated patient PBMC, selected 25-Gy-irradiated leukemia cells, 50-Gy-irradiated PHA-B or 75-Gy-irradiated EBVinduced B cell lines (LCL). Cultures were restimulated up to five times with the same stimulator cells every 10-14 days, together with 25-Gy-irradiated normal donor lymphocytes expanded with anti-CD3 (Biosource International, Inc., Camarillo, CA, USA) and IL-2 as feeder cells in RPMI/CM with IL-2 and 10 ng/ml of human recombinant interleukin-7 (rh IL-7, Biosource International).
T cell phenotype. The phenotype of responder lymphocytes was analyzed by flow cytometry with anti-CD4-phycoerythrin (PE), CD8-peridinin chlorophyll (PerCP), CD57-fluorescein isothiocyanate (FITC) and CD25-allophycocianin (APC) monoclonal antibodies (Becton Dickinson, San Jose, CA, USA). CD57 was used as a marker of effector CTL. 18 Flow cytometric assay was performed using FACSCalibur (Becton Dickinson) and analyzed with CellQuest software (Becton Dickinson).
Colony inhibition assay. CML progenitor inhibitory activity of CTL was measured by CFU-GM colony inhibition as previously described. 19 In brief, after centrifugation at 1000 rpm for 1 min providing cell-to-cell contact, 2 Â 10 6 PBMC of CML patient and third-party CML patient (viability 498% by trypan blue exclusion) were cocultured with responder cells, at effector:target (E:T) ratios of 10:1, 3 PHA-B, LCL, autologous lymphocytes, K562 and Daudi cells were coincubated with responder lymphocytes at E:T ratios of 10:1, 5:1 and 1:1 or without target or stimulator cells in 60-well Terasaki trays; trays were centrifuged at 700 rpm for 1 min. Trays were read for total fluorescence emission and then placed in an incubator at 371C 5%CO 2 for 4 h. After incubation, 5 ml of bovine hemoglobin quench (FluoroQuench EB Stain-Quench reagent; One Lambda, Canoga Park, CA, USA) was added to each well, and the fluorescence emission was measured with a Cytofluor fluorescence plate reader (Perkin-Elmer, Boston, MA, USA). The excitation and emission wavelengths were 496 and 520 nm, respectively. CTL lysis was calculated using the following equation: % specific lysis ¼ 1À[(mean test emission À mean blank emission)/ (mean emission without effector-mean blank)] Â 100.
Each experiment was performed in six replicates. As previously reported, the blastic phase CML cells of patient 5 were not suitable for this assay due to spontaneous dye release. 22 CTL activity was instead determined using the FATAL assay. 23 In brief, after target cells were labeled with two dyes (PKH-26 (Sigma-Aldrich, St Louis, MO, USA), and CFSE (Molecular Probes)) and coincubated with effector cells at E:T ratios of 10:1, 5:1 and 1:1, and without effector cells for 4 h. Viable cells were examined by flow cytometry using a FACSCalibur, and analyzed with CellQuest software.
Proliferation assay. The proliferative responses of CTL to leukemia cells, PHA-B, LCL, third-party leukemia cells and autologous lymphocyte controls were examined using a tritiated thymidine ( 3 H-TdR) incorporation assay. Irradiated leukemia cells, autologous lymphocytes, PHA-B and LCL were coincubated in triplicate with 5 Â 10 4 responder cells per well using immunomagnetic beads (Dynabeads) to positively enrich for CD4+ or CD8+ cells. Stimulatorresponder ratios (S:R) were 10:1 for leukemia cells and 1:1 for PHA-B, LCL and autologous lymphocytes. After 5 days incubation in RPMI-CM/10% NABS, cultures were pulsed with 1 mCi of 3 H-TdR per well (Amersham Biosciences, Piscataway, NJ, USA). After 18 h, 3H-TdR incorporation (cpm) was measured using a beta scintillation counter.
T cell receptor TCR Vb analysis. The T cell receptor (TCR) Vb repertoire of CTL was examined by flow cytometry. 18 In brief, 10-14 days after every stimulation (immediately prior to the next stimulation), 5 24 In some cases, T cells bearing distinctive TCR Vb's were positively selected with anti-PE microbeads (Miltenyi Biotec. Inc., Auburn, CA, USA) according to the manufacturer's instruction in further experiments.
RESULTS
Patients and responder pairs studied
HLA typing of seven stimulator-responder pairs is detailed in Table 1 . Three pairs shared three antigens (4,5,6), two were completely mismatched for HLA-A and -B but shared one or two DRB1 antigens (1, 2), two were completely mismatched at DRB1 but shared one or two HLA-A or -B antigens (3, 7) .
Cytotoxicity of bulk cultures
In three of five cases, 14-day bulk CTLs generated after pulsing with patients' PBMC showed nonlineagerestricted cytotoxicity against the stimulator's myeloid leukemia cells, PHA-B and LCL. However, in the two class I-mismatched pairs, no cytotoxicity to LCL was elicited. There was no significant cytotoxicity to K562 cells or Daudi cells indicating that NK-or LAK-like activity did not persist in the bulk cultures (data not shown). After four stimulations with leukemia cells, two of five cases showed a leukemia-restricted response. In case 5, CML blasts did not label consistently with the dye and cytotoxicity was instead determined using the FATAL assay. CTL activities at 10:1 and 1:1 E:T ratios are shown in Table 2 (representative data from three independent experiments). No cytotoxicity was observed against third-party targets completely (HLA 6/6) mismatched with target cells.
CFU-GM inhibition
The 14-day bulk CTLs generated with CML-CP patients' PBMC strongly inhibited CML CFU-GM, but not thirdparty CML CFU-GM, in a dose-dependent manner, with up to 86% colony inhibition at an E:T ratio of 10:1 in five separate experiments (Table 3) . Leukemic CFU inhibition was also demonstrable in the patient with MDS/AML (77.6% inhibition at a 10:1 E:T ratio). The third-party CFU-GM count was often higher in the presence of effector cells, possibly due to the production of hematopoietic growth factors by the CTL. The major population of expanded effector cells in the bulk culture were CD25 positive and included some CD57/CD25 double-positive CD4+ and CD8+ T cells (Table 4 ). These observations HLA-mismatched tissue-restricted T cell H Fujiwara et al confirmed that T cell alloresponses against leukemia could be readily induced in an HLA-mismatched setting.
TCR Vb analysis
The effector T cell repertoire in cultures pulsed 2-4 times with either leukemia cells, LCL or PHA-B was studied in five pairs. TCR Vb analysis revealed discrete expansions of 2-4 Vb families in both CD4+ and CD8+ T cells, which varied between individuals and according to the stimulator used. CD8+ T cells showed more marked selective expansion than CD4+ cells. Examples of both lineagerestricted and nonrestricted Vb expansions are shown in Table 5 . On successive restimulations, there was a trend to increased skewing of specific Vb families in Figure 1 . depleted cells also killed third-party CML cells sharing HLA-A68 (Figure 3 ), but not third-party CML cells sharing HLA-A24 (data not shown). This cytolytic activity was also blocked by anti-HLA class I antibody (data not shown).
Separation of leukemia-or myeloid-reactive CTL from lymphoid-reactive CTL
Discussion
The factors governing HLA-mismatched alloresponses are complex and poorly described. Interactions between the TCR of the responding T cell and the foreign MHC are thought to include a spectrum of recognition patterns from HLA antigen-specific responses, through responses to MHC+peptide, to peptide-specific HLA-independent responses. 25 Additionally, T cells may recognize foreign peptides derived from MHC molecules presented via MHC class I or II, 26 and finally they may also interact physiologically via shared MHC antigen presentation pathways. It is generally assumed that the mismatched alloresponse is dominated by a high frequency of T cell precursors recognizing foreign MHC, with a relatively small component of peptide-specific alloresponses. This concept has recently been challenged by the demonstration that cross-presentation of a variety of peptide antigens is possible. 27, 28 Furthermore, Mutis et al 31 have successfully induced powerful and specific alloresponses to an HLA-A2/ minor antigen HA-1 peptide complex. It therefore appears that such peptide-MHC-specific T cell responses represent a new class of antigenic targets in the context of mismatched stem cell allografts. If such peptides are derived from proteins restricted to myeloid cells, for example, it should be possible to generate tissue-restricted, peptide-specific, T cell responses in HLA-mismatched transplants.
With this possibility in mind, we set out to examine (1) whether mismatched alloresponses to myeloid leukemias could be readily induced, and (2) whether they could be separated from alloresponses to other cells. In unrelated mismatched-pairs chosen for presumable haplotype, class I or II mismatch, we showed that allospecific CTL were readily generated and that such CTL strongly inhibited CML CFU-GM (Tables 2 and 3) . Predictably, the CTL induced by unfractionated peripheral blood from leukemia patients were cytotoxic, not only to the leukemia but also to patient's PHA-B and also, in most cases, to LCL. We next sought to elicit myeloid leukemia-, T cell-or B cell-specific alloresponses by stimulating the responders with lineageselected cells. We used a panel of TCR Vb antibodies to identify clonal responses leading to expansion in specific Vb families. We found TCR Vb expansions common to T cells and myeloid cells, as well as those that were restricted to a single lineage (Figure 1 ). These expansions tended to increase with further restimulations and, when selected, such Vb fractions showed the appropriate lineage specificity. Notably, it was possible to either positively or negatively select the proliferating or cytotoxic leukemiaspecific T cell and remove reactivity to T and B cells (Figures 2 and 3) .
These findings raise several questions. Firstly, what are the antigens on leukemia cells recognized by the alloreacting T cells, and in which category (peptide-specific, peptide+MHC-specific or MHC-specific) do these alloresponses fall? Our preliminary data suggest that undetermined myeloid tissue-specific or myeloid leukemia-specific antigen could be selectively recognized in mismatched S-R pairs, either via nonself HLA-A2 as in S-R pair 1, or via common HLA-A68 as in S-R pair 4 (Figures 2 and 3 ). In addition, in S-R pair 3, data also suggested that third-party CML expressing the same HLA-A24 restriction element was recognized by those responders (data not shown). Recently, Mutis et al 29 identified a CD34+ cell and myeloid leukemia-specific CD4 T-cell clone which was restricted by a nonself HLA-DR allele. They also found that HA-1 peptide can be recognized in an HLA-Amismatched context. 30, 31 It thus appears that tissuerestricted alloresponses can be conserved in HLA-matched and-mismatched configurations. Further studies using blocking antibodies to specific HLA molecules and panels of mismatched targets would be required to better define these issues.
The second question is whether the tissue-restricted alloresponses we observed are strictly leukemia specific and would result in a GVL effect without GVHD. There is in vitro and in vivo data to support this possibility: Clinical trials under way indicate that haploidentical peripheral blood mononuclear cells can successfully be used to stimulate and then eliminate alloreacting T cells resulting in GVHD prevention in pediatric recipients. 32, 33 Our own preclinical studies to selectively deplete alloresponding donor T cells with anti-CD25 immunotoxin employ purified T cells as stimulators. In the HLA-matched setting, this depletion approach eliminates responses to the stimulator T cell while selectively preserving T cells recognizing the recipient myeloid leukemia. 34 Other investigators have used the same limited set of targets (PHA lymphoblasts and myeloid cells) as a basis for defining leukemia-specific T cells which, when adoptively transferred into HLA-matched recipients with relapsed leukemia, did not cause GVHD. 35 Nevertheless, it would be helpful to further screen these mismatched leukemiarestricted candidate T cell lines against tissues of nonhematopoietic origin to confirm their specificity prior to their clinical application. Recently, an important role for NK, LAK and other ''non-MHC-restricted cytotoxic cells'' has been elucidated in the alloresponse to myeloid leukemias. 36 In this study, we have not investigated the possible synergy between T cells and these effectors. Firstly, the culture conditions using cryopreserved cell samples was not conducive to preserving NK cell function. Secondly, we eliminated any cytotoxic contribution of NK and LAK cells by demonstrating that there was no lysis of the highly sensitive K562 cell line. Thirdly, our T cell receptor Vb selection confirmed the cytotoxic properties resided within the T cell population.
In conclusion, these results provide preliminary evidence that discrete lineage-specific T cell responses can be elicited in a diversity of HLA-mismatched situations. They provide a basis for developing selective T cell depletion strategies to prevent GVHD in mismatched transplants while retaining strong GVL reactivity.
